Immunic (NASDAQ:IMUX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other research firms have also weighed in on IMUX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Friday, May 29th. B. Riley Financial dropped their target price on shares of Immunic from $40.00 to $27.00 and set a “buy” rating for the company in a research report on Friday, May 22nd. Roth Capital restated a “buy” rating and issued a $19.00 price target on shares of Immunic in a report on Thursday, May 14th. Wolfe Research began coverage on shares of Immunic in a research report on Friday, May 22nd. They set an “outperform” rating on the stock. Finally, LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $47.57.

Immunic Stock Down 3.1%

IMUX stock opened at $16.06 on Friday. The company has a market cap of $219.06 million, a price-to-earnings ratio of -3.67 and a beta of 1.41. The business has a fifty day simple moving average of $14.45 and a 200-day simple moving average of $12.06. Immunic has a 52 week low of $5.06 and a 52 week high of $16.86.

Immunic (NASDAQ:IMUX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36. As a group, analysts expect that Immunic will post -3.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of large investors have recently modified their holdings of IMUX. OMERS ADMINISTRATION Corp purchased a new stake in shares of Immunic during the 1st quarter valued at about $187,000. Avidity Partners Management LP boosted its holdings in Immunic by 42.6% in the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after acquiring an additional 2,000,000 shares during the period. Renaissance Technologies LLC acquired a new stake in Immunic in the first quarter valued at approximately $1,020,000. XTX Topco Ltd acquired a new stake in Immunic in the fourth quarter valued at approximately $120,000. Finally, Jane Street Group LLC raised its stake in shares of Immunic by 46.8% during the fourth quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after purchasing an additional 91,346 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic News Roundup

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright substantially improved its long-term outlook. The firm raised its EPS forecasts for 2026 through 2030, including reducing projected 2026 losses to $3.18 per share from $7.02 and projecting positive $0.40 EPS in 2030, versus a previous loss estimate of $2.92. HC Wainwright maintained a Buy rating and a $22 price target, supporting the view that Immunic’s pipeline could move the company toward profitability. Analysts Offer Insights on Healthcare Companies: Krystal Biotech and Immunic
• Positive Sentiment: HC Wainwright also raised its third- and fourth-quarter 2026 EPS estimates to losses of $0.74 and $0.68, respectively, from losses of $2.21 and $2.03. Brookline Capital Markets likewise improved its 2026 forecast to a $3.86-per-share loss from $4.34 and raised its third-quarter estimate to a $0.84-per-share loss from $1.07. These revisions suggest analysts expect lower operating losses than previously anticipated.
• Neutral Sentiment: Analyst sentiment is not unanimous. Wall Street Zen upgraded Immunic to “Hold,” while Brookline maintains more cautious estimates, including a slightly wider fourth-quarter 2026 loss forecast of $1.16 per share. The differing views could limit the positive impact of HC Wainwright’s revisions. Immunic Raised to Hold at Wall Street Zen
• Negative Sentiment: Despite the improved forecasts, Immunic remains unprofitable, with the broader consensus calling for a $4.49-per-share loss in the current fiscal year. As a development-stage biotechnology company, IMUX remains dependent on clinical and regulatory progress, so the stock may remain volatile even as longer-term earnings expectations improve.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.